Comment on a meta-analysis comparing hepatic resection or transarterial chemoembolization as initial treatment for hepatocellular carcinoma

by Zhong JH, Xiang BD, Li LQ
Published 2015-10-01

Are another 5 years of adjuvant aromatase inhibitor therapy needed?

by Mo QG, Li DQ, Zhong JH, Wei CY
Published 2016-11-01

Association of the miR-196a2 C>T and miR-499 A>G polymorphisms with hepatitis B virus-related hepatocellular carcinoma risk: an updated meta-analysis

by Zhu SL, Zhong JH, Gong WF, Li H, Li LQ
Published 2016-04-01

Association between three exonuclease 1 polymorphisms and cancer risks: a meta-analysis

by Chen ZY, Zheng SR, Zhong JH, Zhuang XD, Zhou JY
Published 2016-02-01

Postoperative hepatitis B virus reactivation in hepatitis B virus-related hepatocellular carcinoma patients with hepatitis B virus DNA levels <500 copies/mL

by Xie ZB, Wang XB, Fu DL, Zhong JH, Yang XW, Li LQ
Published 2016-07-01

Association between APE1 Asp148Glu polymorphism and the risk of urinary cancers: a meta-analysis of 18 case–control studies

by Zhong JH, Zhao Z, Liu J, Yu HL, Zhou JY, Shi R
Published 2016-03-01

Adefovir dipivoxil is less expensive than lamivudine and associated with similar prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after radical resecti...

by Zhong JH, Ke Y, Zhu SL, Wang L, Luo CP, Gong WF, You XM, Ma L, Xiang BD, Li LQ
Published 2016-11-01